CytomX Regains Nasdaq Compliance, Stabilizes Market Position

CytomX Therapeutics ( (CTMX) ) has shared an announcement.

CytomX Therapeutics announced that it has regained compliance with the Nasdaq’s Minimum Bid Price Requirement after its stock price closed at $1.00 or greater for 10 consecutive trading days as of May 23, 2025. This resolution of the compliance issue stabilizes the company’s market position and avoids potential delisting, which is crucial for maintaining investor confidence and operational stability.

The most recent analyst rating on (CTMX) stock is a Buy with a $3.50 price target. To see the full list of analyst forecasts on CytomX Therapeutics stock, see the CTMX Stock Forecast page.

Spark’s Take on CTMX Stock

According to Spark, TipRanks’ AI Analyst, CTMX is a Neutral.

CytomX Therapeutics shows strong revenue growth and positive technical indicators, supported by a low P/E ratio suggesting undervaluation. However, significant risks from negative equity and cash flow challenges, along with mixed signals from the earnings call and corporate events, moderate the overall outlook.

To see Spark’s full report on CTMX stock, click here.

More about CytomX Therapeutics

CytomX Therapeutics operates in the biotechnology industry, focusing on developing innovative cancer therapies through its proprietary Probody platform, which aims to improve the safety and efficacy of antibody therapeutics.

Average Trading Volume: 5,412,656

Technical Sentiment Signal: Hold

Current Market Cap: $334.8M

Learn more about CTMX stock on TipRanks’ Stock Analysis page.